KNSA (Kiniksa Pharmaceuticals International) Net Interest Margin (Bank Only) %


KNSA Kiniksa Pharmaceuticals International PLC KNSA
54 GF Score
Price $62.95
GF Value $47.92
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Kiniksa Pharmaceuticals International Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

KNSA
54GF Score
Kiniksa Pharmaceuticals International PLC KNSA
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?

Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued. The current stock price of $62.95 is trading 31.4% above its estimated GF Value™ of $47.92. GuruFocus considers Kiniksa Pharmaceuticals International to be Modestly Overvalued.

Key valuation signals for KNSA:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $47.92 vs. price of $62.95 (31.4% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kiniksa Pharmaceuticals International Business Description

Address 105 Piccadilly, Second Floor, London, GBR, W1J 7NJ
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
54GF Score

Get the complete analysis for KNSA

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$62.95
Price
$47.92
GF Value